The Second Generation of COX-2 Inhibitors: Clinical Pharmacological Point of View

Title: The Second Generation of COX-2 Inhibitors: Clinical Pharmacological Point of View

Volume: 4 Issue: 6

Author(s): D. O. Stichtenoth

Affiliation:

Keywords: safety, efficacy, pain, inflammation, valdecoxib, parecoxib, etoricoxib, lumiracoxib

Abstract: Valdecoxib, parecoxib, etoricoxib and lumiracoxib represent the second generation of selective COX-2 inhibitors. In comparison to the first generation, they show an at least equivalent efficacy in the treatment of pain and inflammation. However, the postulated gain of safety is yet difficult to determine and seems to be, if any, small.

Cite this article as:

Stichtenoth O. D., The Second Generation of COX-2 Inhibitors: Clinical Pharmacological Point of View, Mini-Reviews in Medicinal Chemistry 2004; 4 (6) . https://dx.doi.org/10.2174/1389557043403783